Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

1.145 -0.035 (-2.97%)
Streaming Delayed Price Updated: 10:50 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,897,650
Open 1.150
Bid (Size) 1.140 (90)
Ask (Size) 1.150 (618)
Prev. Close 1.180
Today's Range 1.110 - 1.170
52wk Range 0.3450 - 2.105
Shares Outstanding 198,755,831
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
WHY: NEW YORK, NY - (NewMediaWire) - April 24, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
+74.12%
+74.12%
1 Month
-37.43%
-37.43%
3 Month
+109.59%
+109.59%
6 Month
+204.93%
+204.93%
1 Year
+61.24%
+61.24%

More News

Read More
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Key Takeaways From Ocugen Analyst Ratings
Via Benzinga
OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023
Via InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, and Sharecare and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, and QuidelOrtho and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
From The Rosen Law Firm PA
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Chemours, and Ocugen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.